Affordable Access

Publisher Website

Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: A report from the thrombolysis in myocardial infarction (TIMI) trial

Authors
Journal
Journal of the American College of Cardiology
0735-1097
Publisher
Elsevier
Publication Date
Volume
10
Issue
5
Identifiers
DOI: 10.1016/s0735-1097(87)80428-x
Disciplines
  • Medicine

Abstract

To assess the utility of percutaneous transluminal coronary angioplasty after successful thrombolytic therapy for patients with acute myocardial infarction, the outcome of 201 patients who received intravenous recombinant tissue-type plasminogen activator (rt-PA) was analyzed. Reperfusion of the infarct-related artery was observed in 132 patients who were assessed for potential coronary angioplasty at 18 to 48 hours after treatment. Coronary angioplasty was performed in 52 patients (39%). Reasons for not performing angioplasty included unsuitable coronary anatomy, presence of residual stenosis of <60% and the need to perform an earlier procedure. When attempted, coronary angioplasty was successful in 96% of patients and was associated with a decrease in coronary stenosis from 85 to 30%. No patient experienced a major complication associated with coronary angioplasty. Of 36 patients undergoing predischarge coronary angiography after successful angioplasty, the infarct-related artery remained patent in 97.2%. Thus, coronary angioplasty is feasible and safe in patients who achieve coronary reperfusion after intravenous rt-PA for acute myocardial infarction. Not all patients who achieve reperfusion, however, are suitable for coronary angioplasty. When attempted, angioplasty is usually successful and associated with sustained patency of the infarct-related artery.

There are no comments yet on this publication. Be the first to share your thoughts.